Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer

World Journal of Gastroenterology

Volumn 11, Issue 19, 2005, Pages 2975-2980

  Huang, Mei Fang ^a   Zhu, You Qing ^a   Chen, Zhi Fen ^a   Xiao, Jun ^a   Huang, Xin ^a   Xiong, Yong Yan ^a   Yang, Gui Fang ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Cellular phenotype; Gastric cancer; Syndecan 1

Indexed keywords

PROTEIN ANTIBODY; SYNDECAN 1; UVOMORULIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNET RING CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH MUCOSA; TUMOR DIFFERENTIATION;

EID: 20344366808     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i19.2975     Document Type: Article

References (36)

1. plus T-cells in Igμ-deficient/ipr mice. International Immunol 2003; 15: 1045-1048
2. Dull RO, Dinavahi R, Schwartz L, Humphries DE, Berry D, Sasisekharan R, Garcia JG. Lung endothelial heparn sulfates mediate cationic peptide-induced barrier dysfuntion: a new role for the glycocalyx. Am J Physiol Lung Cell Mol Physiol 2003; 285: 986-995
3. Tanabe H, Yokota K, Kohgo Y. Localization of syndecan-1 in human gastric mucosa associated with ulceration. J Pathol 1999; 187: 338-344
4. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-1455
5. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994; 54: 3845-3852
6. Shino Y, Watanabe A, Yamada Y, Tanase M, Yamada T, Matsuda M, Yamashita J, Tatsumi M, Miwa T, Nakano H. Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995; 76: 2193-2201
7. Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Iwaya T, Terashima M, Saito K, Satodate R. Inactivation of the E-cadherin gene in primary gastric carcinomas and gastric carcinoma cell lines. Jpn J Cancer Res 1996; 87: 1153-1159
8. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 1997; 112: 46-54
9. Tajima Y, Shimoda T, Nakanishi Y, Yokoyama N, Tanaka T, Shimizu K, Saito T, Kawamura M, Kusano M, Kumagai K. Gastric and intestinal phenotypic marker expression in gastric carcinomas and its prognostic significance: immunohistochemical analysis of 136 lesions. Oncology 2001; 61: 212-220
10. Koseki K, Takizawa T, Koike M, Ito M, Nihei Z, Sugihara K. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer 2000; 89: 724-732
11. Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K, Riddell RH, Sipponen P, Watanabe H. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000; 24: 167-176
12. Koseki K, Takizawa T, Koike M, Ito M, Nihei Z, Sugihara K. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer 2000; 89: 724-732
13. Adams JC, Kureishy N, Taylor AL. A role for syndecan-1 in coupling fascin spike formation by thrombospondin-1. J Cell Biol 2001; 152: 1169-1182
14. Katsuyama T, Spicer SS. Histochemical differentiation of complex carbohydrates with variants of the concanavalin A horse-radish peroxidase method. J Histochem Cytochem 1978; 26: 233-250
15. Ohmura K, Tamura G, Endoh Y, Sakata Kq Takahashi T, Motoyama T. Microsatellite alterations in differentiated-type adenocarcinomas and precancerous lesions of the stomach with special reference to cellular phenotype. Hum Pathol 2000; 31: 1031-1035
16. Egashira Y, Shimoda T, Ikegami M. Mucin histochemical analysis of minute gastric differentiated adenocarcinoma. Pathol Int 1999; 49: 55-61
17. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S, Takeichi M. Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 1991; 139: 17-23
18. Mali M, Jaakkola P, Arvilommi AM, Jalkanen M. Sequence of human syndecan indicates a novel gene family of integral membrane proteoglycans. J Biol Chem 1990; 265: 6884-6889
19. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8: 365-393
20. Elenius K, Jalkanen M. Function of the syndecans-a family of cell surface proteoglycans. J Cell Sci 1994; 107: 2975-2982
21. Saunders S, Jalkanen M, O'Farrell S, Bernfield M. Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol 1989; 108: 1547-1556
22. Hayashi K, Hayashi M, Jalkanen M, Firestone JH, Trelstad RI, Bernfield M. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron micro-scope study. J Histochem Cytochem 1987; 35: 1079-1088
23. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 2003; 43: 157-164
24. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stage of differentiation. Cell Regul 1989; 1: 27-35
25. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, Sanderson RD. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998; 91: 2679-2688
26. Rapraeger AC, Ott VL. Molecular interactions of the syndecan core proteins. Curr Opin Cell Biol 1998; 10: 620-628
27. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997; 74: 482-491
28. Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki T, Saitoh Y, Kohgo Y. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Clin Res 2001; 92: 1074-1081
29. Park PW, Gerald BP, Hinkes MT, Bernfield M. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 2001; 411: 98-102
30. Gabbert HE, Mueller W, Schneiders A, Meier S, Moll R, Birchmeier W, Hommel G. Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int J Cancer 1996; 69: 184-189
31. Day RM, Hao X, Ilyas M, Daszak P, Talbot IC, Forbes A. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 1999; 434: 121-125
32. Barbareschi M, Maisonnenve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C. High syndecan-1 expression in breast carcinoma is related to an aggressive pheotype and to poorer prognosis. Cancer 2003; 98: 474-483
33. Egashira Y. Mucin histochemical study of differentiated adenocarcinoma of stomach. Nippon Shokakibyo Gakkai Zasshi 1994; 91: 839-848
34. Blok P, Craanen ME, Dekker W, Tytgat GN. Loss of E-cadherin expression in gastric cancer. Histopathology 1999; 34: 410-415
35. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kim V, Jutersek A, Teuchmann S, Benz M, Prijon T. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57: 324-329
36. Takahashi H, Endo T, Yamashita K, Arimura Y, Yamamoto H, Sasaki S, Itoh F, Hirata K, Imamura A, Kondo M, Sato T, Imai K. Mucin phenotype and microsatellite instability in early multiple gastric cancers. Int J Cancer 2002; 100: 419-424